Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01438749 · ClinicalTrials.gov registry record · Phase 1

A Study of The Abuse Liability Potential of RO4917838 in Recreational Drug Users

A Phase 1 study of Healthy Volunteer, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 1
Development phase
177
Enrollment target
1
Study location

NCT01438749: Completed Phase 1 study of Healthy Volunteer, sponsored by Hoffmann-La Roche.

NCT01438749 is a Phase 1 study of Healthy Volunteer that has completed, run by Hoffmann-La Roche. The registered enrollment target is 177 participants, below the 200-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (11% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01438749, a Phase 1 study of Healthy Volunteer, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 1
Development phase
177 participants
Enrollment target
1
Study location

Study Summary

This randomized, placebo- and active-controlled, crossover study will evaluate the abuse liability potential of RO4917838 in recreational drug users. In a pre-study (Part 1), subjects will receive a single dose of either diazepam or placebo in an inpatient crossover design, with a wash-out period of at least 10 days between treatments. Subjects who are clearly able to distinguish the positive control from placebo will be enrolled in the main study (Part 2) and will be randomized to single oral doses of RO4917838 (3 dose levels), diazepam and placebo in a double-blind, double-dummy inpatient crossover design. Washout-periods between the 5 treatment periods in Part 2 will be at least 10 days.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG RO4917838
  • DRUG diazepam

Study Locations (1)

Utah

  • - Salt Lake City

Trial Details

FieldValue
Enrollment Target 177 participants
Start Date 2011-10
Est. Completion 2012-05
Phase Phase 1
Hoffmann-La Roche

909 total trials

What the finished NCT01438749 record still lists

NCT01438749 is an interventional study that assigns participants to a tested intervention. The registered 177 participants enrollment target is mid-sized for trials with a published cap, below the 200-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (11% lower).

The record links to 1 condition, with Healthy Volunteer appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT01438749 reports a single indexed study location in Utah.

Frequently Asked Questions

What is clinical trial NCT01438749 about?

NCT01438749 is a clinical study titled "A Study of The Abuse Liability Potential of RO4917838 in Recreational Drug Users". This randomized, placebo- and active-controlled, crossover study will evaluate the abuse liability potential of RO4917838 in recreational drug users. In a pre-study (Part 1), subjects will receive a single dose of either diazepam or placebo in an inpatient crossover design, with a wash-out period of...

What is the current status of trial NCT01438749?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 177 participants. The study started on 2011-10. Estimated completion is 2012-05.

What conditions does trial NCT01438749 study?

This clinical trial studies the following conditions: Healthy Volunteer.

What interventions are being tested in trial NCT01438749?

The interventions under investigation include: Placebo (DRUG), RO4917838 (DRUG), diazepam (DRUG).

Who is sponsoring clinical trial NCT01438749?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01438749 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01438749's enrollment target sits among peer trials

177 22nd of 112 higher than 91 of 112 other Healthy Volunteer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Volunteer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05491551 · 177 participants · NA

    Alcohol-ROC-Training

  • NCT06108050 · 177 participants · Phase 1

    JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

  • NCT06575712 · 177 participants · NA

    Coping Skills Training for Symptom Management and Daily Steps (Step Up)

  • NCT06674980 · 177 participants · NA

    Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01438749, the US trial registry maintained by the National Library of Medicine. NCT01438749 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.